HRV Pharma - MD & CEO, Hari Kiran Chereddi, featured in Express Pharma, discusses India's shift from generics to biosimilars leadership.
Key Highlights from the Feature
Hari Kiran emphasizes India's potential in advanced biologics for underserved markets. Key points include:
-
Transitioning beyond low-cost generics to high-value biosimilars.
-
Building resilient supply chains for global pharma demands.
-
Leveraging India's manufacturing strengths in complex APIs.
Why Biosimilars Matter Now
Biosimilars offer cost-effective alternatives to expensive biologics, expanding access to treatments for chronic diseases. India's regulatory progress positions companies like HRV Pharma as key players in this $100B+ market by 2030.
Full Coverage Below
See the complete Express Pharma clipping for detailed analysis.
